Nav: Home

Protease-activated receptors differentially regulate endothelial nitric oxide synthase

March 31, 2016

Protease-activated receptors (PARs) are a family of G-protein-coupled receptors that are primarily expressed in cells of the vasculature and known for their involvement in regulation of vascular tone. These receptors induce endothelium-dependent relaxation via production and release of a potent vasodilator, nitric oxide (NO), and therefore, play an important role in the function of the endothelium. Disruption of endothelial function can lead to the development of cardiovascular diseases such as atherosclerosis and hypertension. There are four members of the PAR family, PAR-1 through -4, and unlike traditional receptors, which are activated by coupling with a ligand, these receptors are uniquely irreversibly activated via cleavage by serine proteases that expose a neo-N-terminus, which acts as a self-activating peptide. PAR-1, -3 and -4, are directly activated by thrombin, a serine protease responsible for platelet aggregation, endothelial cell activation, and other important responses in the vasculature. PAR-2 is activated by trypsin-like enzymes and can respond to thrombin only through transactivation by PAR-1.

It was known that several members of the PAR family modulate the production of NO via post-translational modification of endothelial nitric oxide synthase (eNOS). PARs have been shown to phosphorylate this enzyme at two specific regulatory sites. When eNOS-Ser-1177/-1179 (human/bovine) is phosphorylated, there is an increase in eNOS activity followed by an immediate increase in the production of NO. In contrast, when eNOS-Thr-495/-497 (human/bovine) is phosphorylated, eNOS activity is down regulated, which leads to a decrease in NO production. Motley and colleagues have previously demonstrated the reciprocal regulation of the phosphorylation of these two sites on eNOS by PARs using bovine aortic endothelial cells (BAECs) and human umbilical vein endothelial cells (HUVECs). In addition, PARs phosphorylate the two eNOS sites via different G protein-dependent signal transduction pathways. They showed that thrombin and a selective PAR-1 activating peptide (AP), TFLLR, modulate eNOS negatively by phosphorylating eNOS at the Thr-495 site and signals through a Rho/ROCK dependent-pathway that is coupled to G12/13. Activation of PAR-2 via PAR-1 transactivation or using an activating peptide specific for PAR-2, SLIGRL, phosphorylates eNOS at Ser1177 through Gq, which is coupled to Ca2+, a PKC-δ-sensitive, and PI3K/AKT-independent signaling pathway.

In the March 2016 issue of Experimental Biology and Medicine Tillery et al provide evidence of a deviation from the classical role of PARs in mediating the regulation of eNOS phosphorylation in humans. In this study, primary human coronary artery endothelial cells (HCAECs) were used as a model system to characterize the signaling potential of PARs. Thrombin was observed to primarily regulate the positive site of eNOS, inducing phosphorylation of eNOS-Ser-1177. Activation of PAR-1 and PAR-2 using specific activating peptide ligands phosphorylated both regulatory sites with evidence of dual signaling pathways. However, only PAR-1 activation resulted in an increase in NO metabolites, which favors vasodilation, while selective PAR-2 activation prevented NO production, which favors vasoconstriction. In addition, they were able to characterize the functional role of PAR-3, which induced eNOS-Thr-495 phosphorylation only; whereas PAR-4, which was not expressed in these cells. These are novel findings, which characterize PAR-mediated eNOS/NO signaling in relevant HACECs in the critical vasculature altered in ischemic heart disease. Tillery reflected, "Being able to understand PAR signaling in the human vasculature will aid in targeting specific molecular sites in the vasculature for therapeutic treatments to circumvent endothelial dysfunction and decrease the prevalence of other associated cardiovascular diseases."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said "the studies by Motley and colleagues provides unique insight into PAR signaling which could lead to new therapies to treat vascular diseases".
Experimental Biology and Medicine is a journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership visit If you are interested in publishing in the journal please visit

Society for Experimental Biology and Medicine

Related Phosphorylation Articles:

Immune system can spot tell-tale change in identity of cancer antigens -- study
A new study has identified novel mechanisms whereby T cells may be able to distinguish an emerging class of targets specifically increased on cancer cells.
Cracking the code of Huntington's disease
Huntington's disease is caused by a gene mutation that causes a protein to build up in the brain.
Researchers mapped interactions of key group of human proteins, the protein phosphatases
Unlike with protein kinases, the current knowledge of protein phosphatase functions remains fragmentary.
FASEB Science Research Conference: Protein Kinases and Protein Phosphorylation
This conference focuses on the biology of protein kinases and phosphorylation signaling.
Researchers identify phosphorylation process vital to cancer growth
Scientists at VIB-KU Leuven have identified a new mechanism that impacts tumor growth.
Controlling the body clock
A new study from the laboratory of Hiroki Ueda at the RIKEN Quantitative Biology Center investigates circadian timekeeping with a novel approach to creating genetic knock-out rescue mice.
Discovery opens door to new Alzheimer's treatments
Australian researchers have shed new light on the nerve cell processes that lead to Alzheimer's disease, overturning previously held ideas of how the disease develops and opening the door to new treatment options that could halt or slow its progression.
Heat shock regulator controlled by on/off switch and phosphorylation
Whitehead Institute researchers have determined how the master transcriptional regulator of the heat shock response, known as heat shock factor 1 (HSF1), is controlled in yeast.
Fast driver spotted on evolutionary tracks
A previously unrecognized strategy that living things use to rapidly diversify and evolve has now been uncovered.
Drivers of evolution hidden in plain sight
A study published in Science reconstructs the evolutionary history of thousands of protein modifications in 18 related species.

Related Phosphorylation Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Bias And Perception
How does bias distort our thinking, our listening, our beliefs... and even our search results? How can we fight it? This hour, TED speakers explore ideas about the unconscious biases that shape us. Guests include writer and broadcaster Yassmin Abdel-Magied, climatologist J. Marshall Shepherd, journalist Andreas Ekström, and experimental psychologist Tony Salvador.
Now Playing: Science for the People

#514 Arctic Energy (Rebroadcast)
This week we're looking at how alternative energy works in the arctic. We speak to Louie Azzolini and Linda Todd from the Arctic Energy Alliance, a non-profit helping communities reduce their energy usage and transition to more affordable and sustainable forms of energy. And the lessons they're learning along the way can help those of us further south.